ISNES, Belgium, March 13, 2018 /PRNewswire/ -- VolitionRx Limited
(NYSE AMERICAN: VNRX) ("Volition"), a multi-national life
sciences company focused on developing simple, easy to use, cost
effective blood tests designed to help diagnose a range of cancers,
announced today the closing of its previously announced
underwritten public offering of 3,500,000 shares of common stock at
a public offering price of $2.40 per
share for gross proceeds of $8.4
million, before deducting underwriting discounts,
commissions and estimated offering expenses payable by
Volition. All of the shares of common stock sold in the
offering were offered by Volition.
Oppenheimer & Co. Inc. acted as the sole book-running
manager for the offering. National Securities Corporation, a
wholly owned subsidiary of National Holdings Corporation (NasdaqCM:
NHLD), acted as a co-manager in connection with the offering.
Volition intends to use the net proceeds of the offering for
continued product development, clinical studies, product
commercialization, working capital, and other general corporate
purposes.
The securities described above were issued by Volition pursuant
to a "shelf" registration statement on Form S-3 (File No.
333-206781) previously filed with and declared effective by the
Securities and Exchange Commission ("SEC") on September 18, 2015. A final prospectus
supplement and an accompanying prospectus relating to the offering
were filed with the SEC on March 9,
2018 and are available on the SEC's website located at
http://www.sec.gov. Electronic copies of the final prospectus
supplement and the accompanying prospectus relating to the offering
may be obtained from: Oppenheimer & Co. Inc., Attention:
Syndicate Prospectus Department, 85 Broad St.,
26th Floor, New York,
NY 10004, by telephone at (212) 667-8563 or by email at
EquityProspectus@opco.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any securities described herein,
nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Volition
Volition is a multi-national life sciences company focused on
developing simple, easy to use, cost effective blood tests designed
to help diagnose a range of cancers. The tests are based on
the science of Nucleosomics®, which is the practice of identifying
and measuring nucleosomes in the bloodstream or other bodily fluid
- an indication that disease is present.
As cancer screening programs become more widespread, Volition's
products aim to help to diagnose a range of cancers quickly,
simply, accurately and cost effectively. Early diagnosis has
the potential to not only prolong the life of patients, but also to
improve their quality of life. Volition's research and
development activities are currently centered in Belgium, with additional offices in
London, Texas and Singapore, as the company focuses on bringing
its diagnostic products to market first in Europe, then in the U.S. and ultimately,
worldwide.
For more information about Volition, visit Volition's website
https://volitionrx.com/ or connect with us via:
Twitter: https://twitter.com/volitionrx
LinkedIn: https://www.linkedin.com/company/volitionrx
Facebook: https://www.facebook.com/VolitionRx/
YouTube: https://www.youtube.com/user/VolitionRx
The contents found at Volition's website address, Twitter,
LinkedIn, Facebook, and YouTube are not incorporated by reference
into this press release and should not be considered part of this
press release. The addresses for Volition's website, Twitter,
LinkedIn, Facebook, and YouTube are included in this press release
as inactive textual references only.
Media/Investor Contacts
Louise Day, Chief Marketing &
Communications Officer
l.day@volitionrx.com
+44 (0)7557 774620
Scott Powell, Executive Vice
President, Investor Relations
s.powell@volitionrx.com
+1 (646) 650 1351
Joseph Green, Edison Advisors
jgreen@edisongroup.com
+1 (646) 653 7030
Safe Harbor Statements
Statements in this press release may be "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, that concern matters that involve risks and
uncertainties that could cause actual results to differ materially
from those anticipated or projected in the forward-looking
statements. Words such as "expects," "anticipates," "intends,"
"plans," "aims," "targets," "believes," "seeks," "estimates,"
"optimizing," "potential," "goal," "suggests," "could," "would,"
"should," "may," "will" and similar expressions identify
forward-looking statements, and include statements regarding the
public offering, including the intended use of proceeds from the
offering. Volition's actual results, and the timing of
events, may differ materially from those indicated in these
forward-looking statements due to numerous risks and
uncertainties. Risks and uncertainties include those
identified under the heading "Risk Factors" in Volition's most
recent Annual Report on Form 10-K and Quarterly Reports on Form
10-Q and in the final prospectus supplement related to the offering
to be filed with the SEC on or about the date hereof (copies of
which may be obtained at www.sec.gov), as well as other risks and
uncertainties identified in documents that Volition files with the
SEC from time to time. These statements are based on current
expectations, estimates and projections based, in part, on
assumptions made by management. These statements are not
guarantees of future performance and involve risks, uncertainties
and assumptions that are difficult to predict.
Forward-looking statements are made as of the date of this release,
and, except as required by law, Volition does not undertake an
obligation to update its forward-looking statements to reflect
future events or circumstances.
Nucleosomics®, NuQ® and HyperGenomics® and their respective
logos are trademarks and/or service marks of VolitionRx Limited and
its subsidiaries. All other trademarks, service marks and trade
names referred to in this press release are the property of their
respective owners.
View original
content:http://www.prnewswire.com/news-releases/volitionrx-announces-closing-of-84-million-public-offering-of-common-stock-300613289.html
SOURCE VolitionRx Ltd